Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ELI-002 7P
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Elicio Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Elicio Therapeutics Announces Completion of Merger with Angion Biomedica
Details : The combined company will focus on the advancement of its clinical development program, ELI-002, a therapeutic cancer vaccine designed with Elicio’s proprietary lymph node-targeting AMP technology, being evaluated in patients with mKRAS-driven solid tu...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 01, 2023
Lead Product(s) : ELI-002 7P
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Elicio Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : ELI-002
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Elicio Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Elicio Therapeutics and Angion Enter into Definitive Merger Agreement
Details : The combined company will focus on advancing Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology to develop immunotherapies, with a focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 17, 2023
Lead Product(s) : ELI-002
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Elicio Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : ANG-3070
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ANG-3070, an oral tyrosine kinase inhibitor (TKI), in patients with primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 29, 2022
Lead Product(s) : ANG-3070
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ANG-3070
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ANG-3070 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 24, 2022
Lead Product(s) : ANG-3070
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ANG-3070
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis
Details : ANG-3070 is an oral tyrosine kinase inhibitor targeting platelet-derived growth factor receptor alpha and beta and Discoidin Domain Receptors 1 and 2 (DDR1 and DDR2), tyrosine kinase receptors linked to the development of fibrosis in the kidneys and lung...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 16, 2022
Lead Product(s) : ANG-3070
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Terevalefim
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results from the Phase 2 GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2021
Lead Product(s) : Terevalefim
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Terevalefim
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ANG-3777 is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2021
Lead Product(s) : Terevalefim
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ANG-3070
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The presentation describes preclinical data from a study of ANG-3070 in a mouse unilateral ureteral obstruction (UUO) model, a well-established model for obstructive renal disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 05, 2021
Lead Product(s) : ANG-3070
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Terevalefim
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase III
Sponsor : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The overall safety profile of ANG-3777 in this trial was consistent with the overall experience in its clinical development program and consistent with the published literature in this patient population.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 26, 2021
Lead Product(s) : Terevalefim
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Sponsor : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ANG-3070
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 1 study was a randomized, double-blind, and placebo-controlled study in healthy volunteers conducted in Australia to assess the safety, tolerability, pharmacokinetics, and food effect of ANG-3070 dosed orally.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 03, 2021
Lead Product(s) : ANG-3070
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable